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BCR–ABL1-induced downregulation of WASP in
chronic myeloid leukemia involves epigenetic
modification and contributes to malignancy
Welbert O Pereira1,2, Daniel D De Carvalho3,4, Maria Emilia Zenteno1, Beatriz F Ribeiro5, Jacqueline F Jacysyn1,6, Luiz R Sardinha2,
Maria A Zanichelli7, Nelson Hamerschlak8, Gareth E Jones9, Katia B Pagnano5, Fabiola A Castro10, Yolanda Calle11,13 and
Gustavo P Amarante-Mendes*,1,12
Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by the BCR–ABL1 tyrosine kinase (TK). The development
of TK inhibitors (TKIs) revolutionized the treatment of CML patients. However, TKIs are not effective to those at advanced phases
when amplified BCR–ABL1 levels and increased genomic instability lead to secondary oncogenic modifications. Wiskott–Aldrich
syndrome protein (WASP) is an important regulator of signaling transduction in hematopoietic cells and was shown to be an
endogenous inhibitor of the c-ABL TK. Here, we show that the expression of WASP decreases with the progression of CML,
inversely correlates with the expression of BCR–ABL1 and is particularly low in blast crisis. Enforced expression of BCR–ABL1
negatively regulates the expression of WASP. Decreased expression of WASP is partially due to DNA methylation of the proximal
WASP promoter. Importantly, lower levels ofWASP in CML advanced phase patients correlate with poorer overall survival (OS) and
is associated with TKI response. Interestingly, enforced expression of WASP in BCR–ABL1-positive K562 cells increases the
susceptibility to apoptosis induced by TRAIL or chemotherapeutic drugs and negatively modulates BCR–ABL1-induced
tumorigenesis in vitro and in vivo. Taken together, our data reveal a novel molecular mechanism that operates in BCR–ABL1-
induced tumorigenesis that can be used to develop new strategies to help TKI-resistant, CML patients in blast crisis (BC).
Cell Death and Disease (2017) 8, e3114; doi:10.1038/cddis.2017.458; published online 12 October 2017
Chronic myeloid leukemia (CML) is a hematological
malignancy caused by the chromosome translocation t
(9:22) (q34;q11), which originates the oncogene BCR–
ABL1. BCR–ABL1 is a protein composed of multiple
domains involved in the initiation of a complex signaling
transduction cascade.1,2 The BCR portion of the oncopro-
tein contains a domain with serine and threonine kinase
activity and regions that bind to Src homology-2 (SH2)
domains, whereas the c-ABL portion contains SH3, SH2
and the tyrosine kinase (SH1) domains, in addition to four
proline-rich domains, a nuclear translocation signal, a DNA-
and an actin-binding domains.3 Binding of BCR–ABL1 to
actin filaments was shown to contribute to transformation.
Importantly, the tyrosine kinase (TK) activity is necessary for
the transformation potential of BCR–ABL13,4 Particularly,
BCR–ABL1 TK activity induces a strong resistance to both
intrinsic and extrinsic pathways of apoptosis,5 for instance,
by inducing overexpression of BCL-XL
6 and MCL-17 and
downregulating TRAIL.8 Therefore, it is not surprising that
the development of specific inhibitors directed to the TK
catalytic site of BCR–ABL1, such as imatinib mesylate,
revolutionized the treatment of CML patients.9
The evolution of CML comprehends three stages: chronic,
accelerated and blast phases. In chronic phase (CP), the bulk
of leukemic stem cells remains capable of undergoing
differentiation, leading to the excessive production of mature
granulocytes. In the accelerated phase (AP), differentiation
becomes arrested, and the severe disease phenotype is
caused by the proliferation of immature blasts, which
increases in the BC.3,10 Mechanisms of imatinib resistance
are multifactorial and include point mutations within
the BCR–ABL kinase domain,11,12 BCR–ABL gene
amplification,11 decreased intracellular drug availability13
and activation of alternative signaling oncogenic
pathways.14,15 In the advanced phases, patients present a
stronger resistance to imatinib or other second- and third-
generation TK inhibitors (TKIs),16 indicating an unmet need for
improved therapeutic approaches in CML treatment.
BCR–ABL1 is the indispensable genetic modification
responsible for CML,3,17,18 but other secondary19 genetic
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and epigenetic changes were also shown to contribute to
malignancy, including resistance to TKIs.20 Although poorly
understood, disturbance of the hematopoietic compartment is
an evident phenomenon in CML that includes failure in
differentiation of the stem cells in the bone marrow21 and
inefficient function of mature leukocytes.22–24 Interestingly,
these events are similar to those observed in patients with
Wiskott–Aldrich syndrome (WAS), an immunodeficiency
caused by the dysfunction of WAS protein (WASP).25 In
addition, CML patients in BC also share symptoms with WAS
patients, such as spontaneous bleeding, petechiae, ecchy-
mosis, thrombocytopenia, enlargement of the spleen and
increased susceptibility to infections.26–28WASP is an adaptor
protein exclusively expressed in hematopoietic cells capable
of promoting actin polymerization.29 Important to our work,
WASP was shown to act as an endogenous inhibitor of the
TKs LCK, FYN and c-ABL.30–32
Here, we show that expression of WASP inversely
correlates with BCR–ABL1 levels and the progression of the
disease in CML patients. BCR–ABL1 downregulatesWASP in
part by epigenetic modification of its proximal promoter. Most
importantly, downregulation of WASP contributes to the
resistance to apoptosis and to BCR–ABL1-induced tumor-
igenesis. Therefore, WASP may serve as a molecular marker
of prognosis, as well as a potential target for combined
antitumor therapies for CML.
Results
WASP is downregulated in BCR–ABL1-positive cell lines
and CML patients by a mechanism that involves epige-
netic modification. Initially, we sought to investigate the
expression of WASP in CML patients and in BCR–ABL1-
positive cell lines. We found that PBMC from CML patients
expressed significantly lower levels ofWASP, comparing with
healthy donors (Figure 1a). CML patients in the CP presented
lower levels of WASP and its expression was decreased
during the progression of the disease to accelerated and
blast phases (Figure 1b). Importantly, PBMC from patients
resistant to TKI exhibited significantly lower levels of WASP
compare with patients responsive to TKI (patients who
achieved the complete cytogenetic remission (CCyR) and
major molecular remission (MMR) after treatment with
imatinib and dasatinib). Patients responsive to TKI were no
different from either healthy individuals or CML patients at
diagnosis (Figure 1b). These data indicate that WASP
expression is linked to CML patient’s response to TKIs
therapy and to BCR–ABL1 levels. Moreover, we detected that
patients who presented secondary resistance to TKI therapy
(patients who achieved but subsequently lose relevant
response) have higher WASP expression in comparison with
patients who showed primary resistance (patients who did not
reach a benchmark response) (Supplementary Figure 1).
Twenty-one CML patients resistant to TKIs were tested for
BCR–ABL mutation; 9 of them were positive for Y253H (2);
M244V (2); T315I (2); F317L (1); H396R (1) e G250E/Y253H
(1) mutations. There was no association with mutation status
and WASP expression levels (P=0.97; Supplementary
Figure 2).
In addition, the expression levels ofWASP and BCR–ABL1
were inversely correlated (Figure 1c), suggesting that BCR–
ABL1 could potentially be responsible for WASP down-
regulation. In order to investigate this possible cause–effect
relationship, we evaluated WASP protein expression in cell
lines derived from BCR–ABL1-negative leukemia (HL-60,
Jurkat, SKW6.4, THP-1 and U937) and BCR–ABL1-positive
CML patients (K562, BV173, LAMA-84 and KCL22). Unlike
the BCR–ABL1-negative cells, WASP was strongly down-
regulated in BCR–ABL1-positive cell lines (Figure 1d) further
supporting that BCR–ABL1 is a negative regulator of WASP.
Our hypothesis was confirmed by transducing BCR–ABL1 in
the HL-60 and Jurkat cell lines, thereby producing HL-60.
BCR–ABL1 and Jurkat.BCR–ABL1 cells. Enforced expres-
sion of BCR–ABL1 induced a strong suppression of WASP,
observed at both mRNA and protein levels (Figure 1e).
Efficacy of BCR–ABL1 transduction was confirmed by
immunoblot using primary antibodies against c-ABL/BCR–
ABL1 (to verify its expression) or to phosphotyrosine (to verify
its activity) (Figure 1e). These results show that expression of
BCR–ABL1 inhibits WASP at both mRNA and protein levels.
As most of BCR–ABL1-mediated signal transduction is
dependent on its TK activity, we tested whether treatment with
imatinib could reinstate the expression of WASP in BCR–
ABL1-positive cells. To our surprise, the inhibition of the TK
activity of BCR–ABL1 did not result in WASP re-expression in
K562, BV173 or HL-60.BCR–ABL1 cells (Figure 2a), even in
the presence of the dual calpain/proteasome inhibitor N-
acetyl-L-leucyl-L-leucyl-L-norleucinal (Figure 2b), as protein
levels of WASP is also tightly controlled by degradation via
calpain-mediated proteolysis.33 These results suggest the
emergence of an additional mechanism that maintains WASP
inhibited independently of constant BCR–ABL1 TK activity.
DNA methylation at CpG sites localized in the promoter
region is a well-known mechanism to stably suppress gene
expression.34 As hematopoietic-specific expression of the
WASP gene was shown to be driven by a promoter located
upstream to the TSS35 (Figures 2c and d), we measured the
DNA methylation levels at CpGs dinucleotide in a 400 bp CpG
island positioned at this promoter region by bisulfite sequen-
cing. We found an inverse correlation between DNA methyla-
tion of WASP promoter and gene expression. CML cell lines
with suppressedWASP, such as BV173 and K562, presented
the higher levels of DNA methylation: 99% and 77%,
respectively. KCL22 (which express low levels of WASP)
presented intermediated levels of DNA methylation: 54%
(Figure 2e). In contrast, THP-1, a BCR–ABL1-negative cell
line, which expresses high amounts of WASP, presented low
level of DNA methylation: 22% (Figure 2e).
Azacytidine (5-AZA) has presented significant therapeutic
results for patients with acute myeloid leukemia and myelo-
dysplastic syndromes, by inducing the demethylation of CpG
sites and the consequent upregulation of silenced genes.36,37
Treatment of CML cell lineswith 1μM5-AZA alone restored the
levels of WASP expression in LAMA-84, BV173 (greatly) and
KCL22 (partially) cell lines, confirming that CpGmethylation is
indeed one epigenetic mechanism involved in BCR–ABL1-
induced WASP suppression (Figure 3). Interestingly enough,
5-AZA failed to restoreWASP levels in K562 cells, although it
restored RASSF1A and GST control genes, suggesting the
BCR–ABL1 inhibition of WASP contributes to malignancy
WO Pereira et al
2
Cell Death and Disease
existence of a further mechanism responsible for down-
regulation of WASP in this cell line. Taken together, our data
suggest that BCR–ABL1 inhibits the expression of WASP via
multiple molecular mechanisms.
Lower WASP expression in PBMC from CML patients in
advanced phases correlates with poor OS and re-
expression of WASP negatively modulates BCR–ABL1-
induced tumorigenesis in vitro and in vivo. Next, we
investigated the biological relevance of decreased levels of
WASP for CML patients. We analyzed the relationship
between the levels of WASP with the OS of the 31 newly
diagnosed CML patients and in 23 CML patients at AP and
BC. For this analysis, we divided the patients in two groups
according to the median of WASP expression. Patients with
WASP levels below the median were called WASP BM, and
patients with WASP levels above the median, were called
WASP AM. There was no significant difference in OS
according to WASP expression at CML diagnosis
(Supplementary Figure 3A). In addition, we observed a
tendency of a lower expression of WASP in high-risk Sokal
patients (Supplementary Figure 3B). Interestingly, when the
OS was calculated just for CML patients in advanced phases,
resistant to TKIs and with significantly lower levels of WASP
compared with healthy donors, we observed that milder
suppression of WASP (levels above median – WASP low)
correlated with longer OS, whereas strong suppression of this
gene (levels below median – WASP very low) correlated with
poorer OS (Figure 4b). Altogether, these data suggest that
the downregulation of WASP by BCR–ABL1 may be relevant
to the CML prognosis, particularly for patients in advanced
phases of disease.
Therefore, we investigated the consequences of re-
expression of WASP on in vitro and in vivo models of BCR–
ABL1-induced tumorigenesis. Using lentiviral transduction,
we enforced the expression of eGFP-WASP or mCherry-WIP
(as a control) in K562 cells, which lacks both WASP and WIP
(WASP-interacting protein) (Figure 4c). First of all, the
expression of WIP, a chaperone for WASP that prevents its
targeting by calpain, thus increasing WASP half-life,33 did not
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Figure 1 WASP is downregulated in CML patients and BCR–ABL1-positive cell lines. (a) The expression of WASP is suppressed in CML patients comparing with healthy
donors (HD). The relative expression of WASP in PBMC was determined by real-time PCR using GAPDH as housekeeping gene (**Po0.01, comparing with HD). Values are
plotted as 2−ΔΔCt. 't' student was used as statistical test. (b) The downregulation of WASP was observed in advanced phases of the disease (AP and BC). (Po0.0001,
comparing with HD). Patients in CCyR showed normal WASP levels, according to the healthy donor control group (Po0.001, comparing with BP). Analysis of variance (ANOVA)
and Bonferronni posttest were used to statistical analysis. (c) The expression ofWASP negatively correlates with BCR–ABL1 expression in CML patients (Po0.0001). Spearman
test was used with linear regression. (d) Western blot showing the expression of WASP in cell lines derived from different leukemia types. BCR–ABL1-negative cell lines express
high levels of WASP, whereas BCR–ABL1-positive cells express discrete or undetectable WASP. Actin was used as loading control. (e) Stable expression of BCR–ABL1 was
induced in HL-60 and Jurkat cell lines by retroviral infection, resulting in downregulation of WASP both at the mRNA and protein levels.GAPDH was used as housekeeping control
for qPCR. Western blots show the increased numbers of tyrosine phosphorylated proteins in BCR–ABL-positive HL-60 and Jurkat cell lines, and the complete WASP silencing
after BCR–ABL1 expression. Actin protein was used as loading control
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result in increased expression of WASP in K562 cells, as
expected after our results showingWASP promoter is silenced
by DNA methylation in these cells (Figure 2e), as described
above. Growth of tumor cells comprehends one important
aspect of tumorigenesis and it is directly associated to the
balance of proliferation and cell death in vitro and in vivo. In line
with this, enforced expression of WASP decreased the growth
of K562 cells compared with K562.WT and K562.WIP
(Figure 4d). We also performed a mixed culture assay with
25%/75%, 50%/50% and 75%/25% of K562.WT (eGFP-
negative) and K562.WASP (eGFP-positive), respectively.
After 7 days of co-culture, the frequency of the cell populations
was determined by flow cytometry. Under all the conditions
tested, the relative percentage of K562.WT to K562.WASP
increased with respect to the initial input (Figure 4e). In
combination, these results suggest that re-expression of
WASP decreases the robustness of the BCR–ABL1-positive
cells, impacting its ability to grow in vitro (Figures 4c–e).
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Figure 2 WASP downregulation is not rescued by imatinib or calpain inhibitor
and involves epigenetic modification. (a and b) Cell lines were treated for 24 h with
10 μM IM and/or the calpain inhibitor N-acetyl-L-leucyl-L-leucyl-L-norleucinal (ALLN),
and western blot was performed to reveal the expression of WASP, WIP and the
status of BCR–ABL1-TK activity. Actin was used as loading control. (c) Scheme of the
distal and proximal promoters of WASP. (d) In silico analysis using UCSC Genome
Browser public data (ww.ucsc.edu) show the presence of CpG sites in the promoters
of WASP (green boxes). (e) CpG methylation status in the proximal promoter of
WASP was evaluated. Black and white circles: methylated and unmethylated
CpG sites
Figure 3 5-AZA treatment restored the levels of WASP expression in some but
not all CML cell lines. (a) Treatment of CML cell lines with 1 μM 5-AZA alone restored
the levels of WASP expression in LAMA-84, KCL22 and BV173, but not in K562 cells.
The relative expression of RASSF1A and GST was used as positive controls for
5-AZA treatment. Two way Anova (Analysis of variance) and Bonferroni post test were
used to determine statistic significance among the groups. *Po 0.05, **Po 0.01,
***Po 0.001
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We next tested the impact of the re-expression of WASP in
K562 cell growth in vivo, using a xenogeneic murine model of
tumor growth. K562.WASP (eGFP-positive) and K562.WIP
(mCherry-positive) were subcutaneously injected in the left and
right flanks of BALB/c nude mice, respectively, and the growth
of the tumorswas followed up to 21 days. In agreement with the
in vitro data, the expression of WASP in K562 drastically
inhibited the in vivo tumor development, as assessed by in vivo
imaging of the whole animal (Figure 4f), and by measuring the
volume and weight of extracted tumors (Figures 4g and h).
Taken together, our data demonstrate that the expression of
WASP has a negative impact on BCR–ABL1-induced tumor-
igenesis both in vitro and in vivo.
WASP sensitizes BCR–ABL1-positive cells to TRAIL- and
chemotherapy-induced apoptosis and interferes with
BCR–ABL1 tumorigenic activity. To complete our study,
we investigated the possible mechanisms involved in the
negative impact of WASP on BCR–ABL1-mediated tumor-
igenesis. In fact, we observed a consistently increased
'spontaneous' apoptosis in cultures of K562.WASP cells
compared with K562.WT (Figure 5a). This could be related to
the fact that expression of WASP in K562 cells resulted in
upregulation of the death receptors DR4 and DR5, and also
their ligand TRAIL (Figure 5b). In fact, when we culture both
cell lines in the presence of the chimeric TRAIL inhibitor,
TRAIL-R2/Fc, we observed a reduction of PI-positive cells
Figure 4 Lower levels of WASP in CML patients at advanced phases may indicate a worse OS and WASP re-expression negatively modulates BCR–ABL1-induced
tumorigenesis. (a) The relative WASP expression values obtained from patients in AP and BP were divided in two groups according to the median: WASP very low for patients
exhibiting a strong WASP downregulation (lower than median), and WASP low for patients presenting a mild WASP suppression (higher than median). (b) Patients with higher
levels of WASP (grouped in WASP low) presented longer OS (median= 61.75 months) comparing with the patients in WASP very low group. Kaplan–Meier was used as
statistical test. (c) K562 cell line was transduced with lentivirus vector to induce the re-expression of WASP (eGFP) or WIP (mCherry). (d) K562.WTor re-expressing WASP or
WIP were plated and the number of cells was counted in Neubauer chamber according to the time point in the graph. ***Po0.001 comparing K562.WASP with K562.WT.
##Po0.01 comparing K562.WASP with K562.WIP. (e) K562.WTwas co-cultured with K562.WASP in three different initial proportions and the frequency of each population was
assessed 7 days later by flow cytometry. (f) K562.WIP (mCherry-positive) and K562.WASP (eGFP-positive) were subcutaneously injected in the right and left flanks of the BALB/c
nude mice, respectively, and the development of the solid tumors was followed and imaging of the tumors was assessed at 21st day. The tumors were collected to determine
volume (g) and weight (h). Student's t-test was used for statistical analysis. *Po0.05
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only in K562.WASP cell samples, and to the level found in
K562.WT cultures (Figure 5a).
As TRAIL was shown to sensitize BCR–ABL1-positive cells
to imatinib mesylate,38 we tested whether the expression of
WASP in K562 cells rendered themmore sensitive to imatinib.
Indeed, imatinib treatment at a dose range achievable in
patients resulted in higher frequency of apoptotic K562.WASP
cells compared with K562.WT (Figure 5c). Finally, we tested
whether the expression of WASP could also sensitize K562
cells to chemotherapy-induced apoptosis. Similarly, K562.
WASP cells were more susceptible to apoptosis induced by
camptothecin, actinomycin D and UV irradiation than K562.
WT cells (Figure 5d). Therefore, increased levels of apoptosis
appear to account for the tumor-suppressor activity mediated
by WASP. These results indicate that the expression of WASP
sensitizes BCR–ABL1-positive cells to apoptosis.
Discussion
The development of TKI was a turning point for the treatment
of CML. However, its efficiency depends on the early
diagnosis, early administration and continuing treatment. In
addition, part of the CML patients do not respond to imatinib
or second- or third-generation TKIs.16 Therefore, the discov-
ery of novel signaling pathways associated with BCR–ABL1-
induced tumorigenesis is still a matter of importance for
patients with BCR–ABL1-positive leukemia. We show here for
the first time that WASP may serve as a molecular marker of
prognosis, as well as a potential target for combined antitumor
therapies for CML.
Initially, we demonstrated that BCR–ABL1 inhibits the
expression of WASP both at mRNA and protein levels.
Particularly important is the fact that downregulation of WASP
seems to take place mostly at the transition of chronic to
advanced phases of the disease. At this point, increased
genomic instability may result in additional genetic abnormal-
ities that are discretely acquired with no significant changes in
the clinical aspects of disease. This includes no relevant
increase in blast numbers, making it difficult to recognize the
molecular evolution of CML patients.16,39,40 The observed
inhibition of WASP expression coincided exactly with this
transition, as patients in CP still express WASP at levels
similar to healthy individuals, whereas patients in AP and BC
has significantly lessWASP (Figure 1b). Therefore, monitoring
the expression of WASP could be useful as a molecular
marker of progression of CML and may help in future
Figure 5 WASP sensitizes BCR–ABL1-positive cells to TRAIL- and chemotherapy-induced apoptosis. (a) K562.WT and K562.WASP were cultured in the presence or
absence of TRAIL-R2/Fc to prevent TRAIL-mediated apoptosis and PI uptake was assesed 48 h later. (b) qPCR shows the upregulation of DR4, DR5 and TRAIL after re-
expression of WASP in K562 cells. (c) K562.WTand K562.WASP were treated with different concentrations of IM and cell death was assessed by the hypodiploid DNA content
(Sub G0) (*Po0.05; **Po0.01; ***Po0.001). (d) Cell lines were treated with camptothecin, actinomycin D and ultra violet (UV) radiation and cell death was assessed after 48 h
by hypodiploid DNA content. Two way ANOVA was used for statistical analysis. ***Po0.001
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therapeutic decisions, such as early switch to more potent TKI
or to use combining chemotherapies.
Besides its potential use as a biomarker for AP/BC, WASP
suppression seems to have a role in the severity of the
disease. First, as mentioned above, WASP levels become
significantly lower in advanced phases of CML (AP+BC). Most
importantly, by dividing these two groups of patients according
to their (diminished) expression of WASP, we observed that
those with very low levels of WASP (below the median) had a
significantly shorter OS than those with low levels (above the
median), independently of the stage of the disease (Figures 4a
and b). Interestingly, another member of the WASP family,
N-WASP, has been implicated in the progression of breast and
colorectal cancer.41–43 Similar to our results, the authors
showed a strong correlation between low levels of N-WASP
and shorter OS/disease-free survival. However, they linked
the increased severity of the disease to an augmented effect of
the absence of N-WASP on tumor invasiveness/metastasis,
which clearly does not apply to our case, because of the
leukemic nature of CML.
The enforced expression of WASP in K562 cells revealed
the biological consequences of WASP suppression in CML.
Our data demonstrate that the strong resistance to apoptosis
conferred by BCR–ABL1 to leukemic cells was attenuated by
the introduction of a WASP-expressing construct. Besides
inducing TRAIL-dependent spontaneous apoptosis, with
participation of the increased expression of DR4 and DR5,
recovery of WASP turned K562 cells sensitive to different
chemotherapeutic drugs, as well as to imatinib. These data
suggest that re-activation of WASP could be an interesting
therapeutic strategy in CML, especially in combination with
imatinib or other TKI. Interestingly, the deficiency of WASP
expression has already been reported to induce or to facilitate
apoptosis in other contexts.44–46
In order to explore this possibility, we investigated the
mechanisms behind WASP downregulation in CML. To our
surprise, treatment of CML cell lines with imatinib did not show
any sign of recovery of WASP, suggesting that the inhibition of
WASP by BCR–ABL1 is either a kinase-independent event or
may undergo a secondary layer of regulation that does not
depend on the constant kinase activity of BCR–ABL1. The
existence of kinase-independent mechanisms derived from
the expression of BCR–ABL1 has been described.47 For
instance, BCR–ABL1 can bind and activate HCK indepen-
dently of its catalytic activity.48 Moreover, the expression of
BCR–ABL1, but not its kinase activity, was shown to be
important to the survival of quiescent CML stem cells.49 In line
with this, we have shown that robust pharmacological
inhibition of BCR–ABL1 TK, as assessed by the disappear-
ance of phosphotyrosine-containing proteins, does not inter-
fere with the strong resistance to apoptosis observed in BCR–
ABL1-positive cell lines, at least for 24 h, when levels of BCL-
XL were significantly reduced.
50,51
The stability of WASP suppression in all tested CML cell
lines led us to investigate the existence of an epigenetic
inhibitory mechanism. Indeed, we found that a CpG island
located at WASP promoter was strongly methylated in BV173
and K562 cell lines, implicating DNA methylation as a novel
mechanism for WASP inhibition.
Re-expression of WASP in the BCR–ABL1-positive cells
hampers both the in vitro and in vivo tumorigenic potential, and
increases sensitivity to imatinib and to chemotherapeutic
drugs, providing a rationale for the development of new
therapeutic strategies aiming to restore the levels of WASP in
BCR–ABL1 leukemia. Our data suggest that one interesting
strategy is combining Azacytidine, an FDA-approved DNA
demethylating agent, to increaseWASPexpression with TKIs,
such as imatinib. Another potential strategy is using gene
therapy approaches to correct WASP expression. Interesting
enough, γ-retroviral and HIV-based lentiviral vectors designed
to correct WASP levels are already in place for patients with
WAS.52–54
One final consequence of our findings is related to proposed
immunotherapy using dendritic cells isolated from CML
patients.55–57 Although there are evidences that the immune
system can potentially eliminate CML cells, particularly
imatinib-resistant BCR–ABL1-positive stem cells, a note of
caution should be added to the use of autologous dendritic
cells, as patients in advanced phase of CML express low
levels of WASP and, therefore, are likely to present impaired
immunological synapses and consequent deficiency in anti-
gen presentation. In fact, using a retrovirus-induced murine
model of CML, Mumprecht and collaborators have shown that
BCR–ABL-expressing DCs do not efficiently induce specific
CTL immune response.22–24
Taken together, we described a new tumor-suppressor
activity forWASPand demonstrated that its expression in CML
interferes with BCR–ABL1-mediated signaling transduction,
increases the sensitivity of leukemic cells to apoptosis and is
associated with a better prognosis of CML patients. Therefore,
the strategies aimed to recover the expression ofWASP, which
are currently being tested for WAS patients,58 may be
potentially considered as a therapeutic approach for some
CML patients.
Materials and Methods
Patients and controls. WASP expression was analyzed in 32 healthy
individual and 85 CML patients (62 CP, 11 AP and 12 crisis blastic phase) treated at
the Euryclides de Jesus Zerbini Transplantation Hospital and the Hematology and
Hemotherapy Center, University of Campinas, State of São Paulo, Brazil, between
April 2003 and October 2010. One patient was diagnosed in August 2015. Thirty-
Table 1 Demographic, clinical and laboratorial features of CML patients
resistant to tyrosine kinase inhibitor therapy
n %
Age (median, years) 54 (21–77)
Gender Male 27 59
Phase Chronic 23 50
Accelerate 11 24
Blast crisis 12 26
Resistance Primary 37 80
Secondary 9 20
Treatment Imatinib (400 mg daily) 29 (3a) 63%
Dasatinib (100–140 mg/day)a 8 17%
Nilotinib (400 mg BID)a 3 11%
Hydrea (1–2 g/day)a 5 7%
Interferon (4.5 million/U/day)a 1 2%
Mutation 9/21b 43
aAfter previous failure with others TKIs
bMutations: 2 Y253H; 2 M244V; 2 T315I; 1 F317L; 1 H396R e 1 G250E/Y253H
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nine patients were responsive to TKIs therapy (imatinib or dasatinib) and 46 were
resistant. Most of patients from responsive groups presented a major molecular
response after dasatinib therapy. The demographic and clinical features of evaluated
patients are shown at Tables 1 and 2 (Supplementary Data).
The study was approved by the local research ethics committees and patients
gave written informed consent for their participation, in accordance with the
Declaration of Helsinki. Demographic and disease characteristics were collected at
baseline. CML diagnosis of the patients enrolled in this study was confirmed by the
demonstration of Philadelphia chromosome in conventional cytogenetics and/or
BCR–ABL1 detection by RT-PCR. Hematologic, cytogenetic and molecular
responses were redefined according to the European LeukemiaNet 2013
recommendations.
Peripheral blood mononuclear cells from patients and controls were isolated
according to standard protocol with the Ficoll–Hypaque 1077 density technique.
Cell lines. All cell lines K562, LAMA-84, KCL22, BV173, Jurkat, HL-60, SKW6.4,
THP-1 and U937 were cultured in RPMI medium 1640 supplemented with 10% fetal
bovine serum, 25 mM Hepes, 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml
streptomycin. HL-60 and K562 cells were obtained from ATCC (Manassas, VA,
USA). LAMA-84 was kindly provided by Dr. James Griffin (Dana-Farber Cancer
Institute, Boston, MA, USA). HL-60.BCR–ABL1 cells were derived from wild-type
HL-60 by retroviral transfection with pSRαMSVp185BCR–ABL1tkneo, as previously
described.51,52 K562 were infected with lentivirus vectors to induce expression of
WASP.GFP and WIP.mchery,59 and sorted using FACS ARIA (Becton-Dickinson,
Franklin Lakes, NJ, USA) to obtain high purity cell lines.
Reagents. For western blot, we used anti-WASP (Santa Cruz Biotechnologies,
Dallas, TX, USA), anti-WIP (Santa Cruz Biotechnologies), anti-c-ABL OP-20
(Oncogene Research Products, La Jolla, CA, USA), anti-Actin (Sigma Aldrich, St.
Louis, MO, USA). TRAIL-R2/Fc protein was generously provided by Dr. Henning
Walczak (Imperial College, London, UK).
Quantitative PCR. Total RNA was extracted using Trizol (Invitrogen, Carlsbad,
CA, USA). RNA concentration and purity were determined spectrophotometrically
by measuring fluorescence at 260 and 280 nm. Three micrograms of RNA was
reverse transcribed into cDNA using Superscript III (Invitrogen) transcription
reagents according to the manufacturer’s instructions. After obtaining the cDNA,
gene expression was quantified by quantitative PCR using Platinum SYBRGreen Kit
(Invitrogen) in Mx3005P detector equipment (Stratagene, Santa Clara, CA, USA).
The following primers were used: BCR–ABL 5´-TGGGTCCAGCGAGAAGGTT-3´
(forward) and 5′-GCATTCCGCTGACCATCAAT-3′ (reverse); GAPDH 5′-GGAGAA
GGCTGGGGCTCAT-3′ (forward) and 5′-TCCTTCCACGATACCAAAGTT-3′
(reverse); TRAIL 5′-AAGGCTCTGGGCCGCAAAATAAAC-3′ (forward) and 5′-CCAA
CTAAAAAGGCCCCGAAAAA-3′ (reverse); DR4 5′-GTACGCCCTGGAGTGACATC
-3′ (forward) and 5′-CCTCGTAGGAGACCCAAGC-3′ (reverse); DR5 5′-CTAGCT
CCCCAGCAGAGAGT-3′ (forward) and 5′-GTGGTGCAGGGACTTAGCTC-3′
(reverse). WASP 5′-GGCTGGTCGGCTGCTCTGGGAACA-3′ (forward) and 5′-
GGTGGTGGGGGTAGCTGGCGTCTGT-3′ (reverse). Results were given as
relative expression represented as 2−ΔΔCt.
Western blot. Protein samples were resolved under reducing conditions as
previously described.45 Separated proteins were transferred onto polyvinylidene
difluoride membranes and reactions were detected with a suitable secondary
antibody conjugated to horseradish peroxidase (Jackson Laboratory, Bar Harbor,
ME, USA and Amersham, Arlington, IL, USA) using enhanced chemiluminescence
(Pierce, Rockford, IL, USA).
Treatments. Cell lines were treated with imatinib mesylate (0.1, 1 and 10 μM),
actinomycin D (5 μM), camptothecyn (100 μM) and UV.C. (400 J/cm2) for 48 h and
cell death was determined by flow cytometry. For TRAIL pathway blockage, cell
lines were treated with 5 μg/ml of TRAIL-R2/Fc for 48 h.
Assessment of cell death. Apoptosis was quantified using the fluorescence-
activated cell sorter (FACS) Calibur flow cytometer (Becton-Dickinson), by analysis
of DNA content as described.51 We also evaluated cell death by propidium iodide
(PI) incorporation for dead cells using flow cytometry. The results represent the
average± S.D. in triplicate samples. Every experiment was repeated at least
three times.
Cell growth analysis and proliferation assays. For absolute count of
cells, 4 × 104 cells K562.WT, K562.WASP, K562.WIP and K562.WASP.WIP were
cultured in six-well plates with 1 ml of medium, and after each 24 h, 0.5 ml of fresh
medium was added to avoid starvation and cellular stress. The absolute number of
the cells was counted in Neubauer chamber each 24 h during 5 consecutive days.
For the co-culture assays, 2 × 105 cells K562.WT (GFP negative) and K562.WASP
(GFP positive) were co-cultured in three different proportions: 25%:75%; 50%:50%;
75%:25%, respectively. The cells were homogenized by pipetting, half part was
discarded and the culture received fresh medium every 24 h. After 7 days of assay,
the frequency of the populations was evaluated by flow cytometry and compared
with day 0. For proliferation assay, K562.WT and K562.WASP were stained with
Violet Cell Trace (Molecular Probes, Invitrogen, Carlsbad, CA, USA) and cultured for
4 days, and the proliferation rate was determined by fluorescence decay using flow
cytometry analysis. The results represent the average±S.D. in triplicate samples.
Every experiment was repeated three times.
Animals and in vivo model of K562-induced solid tumors. Five
million K562.WASP.gfp and K562.WIP.mcherry cells were subcutaneously injected in
the left and right superior flanks of 6–8-week-old, female BALB/c nude mice,
respectively. The tumor growth was followed during 21 days, when the animals were
killed and the tumors were removed to determine weight and volume. Images of the
animals were collected at day 18 after inoculation, and tumors were analyzed
through detection of gfp and mcherry fluorescence using IVIS Spectrum Pre-clinical
In Vivo Imaging System (Perkin Elmer, Waltham, MA, USA). Groups of at least 6
mice were used in each experiment, which was repeated three times. All animals
were housed at our animal facility at the Institute of Biomedical Sciences, University
of Sao Paulo (ICB-USP). This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals of the
Brazilian National Council of Animal Experimentation (http://www.cobea.org.br/).
The protocols were approved by the Animal Ethics Committee of the ICB-USP.
Methylation analysis in WASP promoter. One μg of genomic DNA from
each cell line was bisulfite converted using the Zymo EZ DNA methylation kit (Zymo
Research, Orange, CA, USA), according to the manufacturer’s instructions. To
analyze the DNA methylation status of individual DNA molecules, we amplified by
PCR a 400 bp region upstream to WAS TSS after the bisulfite conversion. The PCR
fragments were cloned into the pCR2.1 vector using the TOPO-TA cloning kit
(Invitrogen). Individual colonies were screened for the insert and the region of
interest was sequenced using M13 primers as previously described.60
5’Azacytidine treatment and induction of DNA demethylation.
The cell lines K562, LAMA-84, KCL22 and BV173 were treated with 1 μM of
Azacytidine for 120 h. The supplemented medium was refreshed every 24 h in order
to maintain the drug concentration during the experiment. Cells were harvested and
RNA was obtained. Real-time PCR was performed to investigate the recovery of
WASP after DNA demethylation. Glutatione S-tranferase-pi 1 (GSTP1) and Ras
association domain family member 4 (RASSF4), which are described as
suppressed genes by CpG methylation in CML cell lines61–63 were used as control
of the efficacy of the treatment, and GAPDH as the housekeeping control.
Statistical analysis. The probability of OS of 31 CML newly diagnosed
patients (clinical and laboratorial features at Table 3,Supplementary Data) according
to WASP expression levels was calculated from CML diagnosis until death or last
follow-up using the Kaplan–Meier method and the log-rank test, using IBM SPSS
Table 2 Demographic, clinical and laboratorial features of CML patients
responsive to tyrosine kinase inhibitors therapy
n %
Age (median, years) 43 (19–73)
Gender Male 24 62
Phase Chronic 39 100
Response CCyR 18 46
MMR 21 54
Treatment Imatinib (400 mg/daily) 18 46
Dasatinib 21 54
Abbreviations: CCyR, complete cytogenetic remission; MMR, major molecular
remission
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software, version 21 (IBM, Armonk, NY, USA). We also calculated the OS of 23
CML patients in advanced phases (AP and BP) resistant to IM 400 mg daily
according to WASP expression levels.
WASP gene expression analysis among healthy individuals and patients' different
groups were performed by using the GraphPad Prism software version 7 (GraphPad
Software Inc., La Jolla, CA, USA).
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